What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer

Author： Trosman Julia R   Weldon Christine B   Schink Julian C   Gradishar William J   Benson Al B  

Publisher： Future Medicine

ISSN： 2042-6305

Source： Journal of Comparative Effectiveness Research, Vol.2, Iss.4, 2013-07, pp. : 461-477

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Change in HER-2/neu Status from Negative to Positive following Treatment in Breast Cancer: A Case Report

By  

Case Reports in Oncology, Vol. 4, Iss. 1, 2011-01 ,pp. : 19-24

Karger

Access to resources Recommend Favorite

HER2: The Neu Prognostic Marker for Breast Cancer

By Tsongalis Gregory J.   Ricci Jr. Andrew  

Critical Reviews in Clinical Laboratory Sciences, Vol. 38, Iss. 2, 1998-03 ,pp. : 167-182

Informa Healthcare

Access to resources Recommend Favorite

HER2/neu vaccines in breast cancer

By Khoo Steven   Ponniah Sathibalan   Peoples George E  

Women's Health, Vol. 2, Iss. 2, 2006-03 ,pp. : 217-223

Future Medicine

Access to resources Recommend Favorite

Targeting Her-2/neu in Breast Cancer: As Easy as This!

By  

Oncology, Vol. 74, Iss. 3-4, 2008-08 ,pp. : 150-157

Karger

Access to resources Recommend Favorite

Her-2/neu Overexpression Due to Polysomy 17 in Breast Cancer: Molecular Testing to Guide Therapeutic Options

By  

Oncology Research and Treatment, Vol. 34, Iss. 7, 2011-06 ,pp. : 356-360

Karger

Access to resources Recommend Favorite